Latest West syndrome Stories
HAYWARD, Calif., Dec. 3, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is again partnering with the Child Neurology Foundation (CNF) in support of the 4(th) annual Infantile Spasms Awareness Week, which will take place December 3 - 12, 2012. As part of this education effort, CNF has developed a website, www.infantilespasmsinfo.org, that provides information on infantile spasms from leading child neurologists and shares stories from...
HAYWARD, Calif., Dec. 3, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced that it is again partnering with the Child Neurology Foundation (CNF) to fund a $30,000 grant to support research into infantile spasms. Dr. Alex R. Paciorkowski of the University of Rochester Medical Center was selected by CNF as the recipient of its annual "Infantile Spasms Research Award." "Questcor has an ongoing commitment to CNF and the entire infantile spasms community,"...
Epilepsy specialists will share their most updated knowledge on how to treat epilepsy and seizures through diets, epilepsy surgery, and anti-epileptic medications. Infantile spasms, Tuberous Sclerosis Complex, Lennox Gastaut Syndrome, Dravet’s Syndrome, genetics in epilepsy, autism, and how to deal with epilepsy emergencies will also be covered. Hackensack, NJ (PRWEB) October 10, 2012 The Northeast Regional Epilepsy Group (NEREG) offers an all-day educational program on the management...
HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced that it has been named the recipient of the Child Neurology Foundation's first-ever Corporate Citizenship Award. The Award honors Questcor's long-term commitment to support the child neurology community as well as its specific efforts to fund education and research related to infantile spasms (IS), a very rare but potentially catastrophic childhood seizure disorder. "One out of...
Grant New UCLA Fellowships for Groundbreaking Pediatric and Adult Epilepsy Research WASHINGTON and SANTA MONICA, Calif., Nov. 10, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP), a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and the Milken Family Foundation, which helps to support basic and applied medical research especially in the areas of epilepsy and cancer, today announced the recipients...
HAYWARD, Calif., Oct. 27, 2011 Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is partnering with the Child Neurology Foundation (CNF) in support of the 3rd annual Infantile Spasms (IS) Awareness Week, which will take place October 24-30, 2011, in conjunction with the Child Neurology Society (CNS) Annual Meeting in Savannah, Georgia. As part of this education effort, CNF has developed a website, www.infantilespasmsinfo.org, that provides information on IS from leading...
HAYWARD, Calif., Oct. 27, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced that it is again partnering with the Child Neurology Foundation (CNF) to fund a $30,000 grant to support research into infantile spasms (IS). For the second year in a row, Catherine Chu-Shore, MD, of Massachusetts General Hospital was selected by CNF as the recipient of the "Logan Infantile Spasms Research Award." "Questcor has an ongoing commitment to CNF and the entire infantile spasms...
DENVER, Oct. 3, 2011 /PRNewswire/ -- Atkins Nutritionals, Inc. is pleased to distribute the results of the recent clinical trial in India which demonstrated the effectiveness of a modified Atkins Diet(TM) in treating infantile spasms, a form of epilepsy, in affected children. The study, published in Seizure: The European Journal of Epilepsy (2011), was conducted at the leading Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. (Logo:...
ANAHEIM, Calif., Feb. 16, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that Standard & Poor's (S&P) will add the Company to the S&P SmallCap 600 Index effective after the close of the U.S. financial markets on February 17, 2011. "Our inclusion in the S&P SmallCap 600 Index reflects our consistent financial performance, and will serve to increase our visibility within the investment community as we continue our efforts to grow sales for...
UNION CITY, Calif., Nov. 3, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010. Acthar provides an important treatment option for children...
